Straits Times Index
3,287.75 -5.38 (-0.16%) S&P 500
5,013.12 -58.51 (-1.15%) Dow
37,866.71 -594.21 (-1.54%) Nasdaq
15,460.95 -251.80 (-1.60%) Bitcoin USD
64,075.18 -608.28 (-0.94%) CMC Crypto 200
1,382.45 -0.12 (-0.01%)
Vincerx Pharma, Inc. (VINC)
| Previous close | 0.9300 |
| Open | 0.9200 |
| Bid | 0.8901 x 100 |
| Ask | 0.9170 x 200 |
| Day's range | 0.8877 - 0.9300 |
| 52-week range | 0.6100 - 9.3720 |
| Volume | |
| Avg. volume | 1,159,501 |
| Market cap | 19.101M |
| Beta (5Y monthly) | 0.81 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.8900 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 9.00 |
ZacksVincerx (VINC) Tumbles on Results From Cancer Therapy Study
Though early-stage results on Vincerx's (VINC) experimental drug did show signs of anti-tumor activity, the share price drops as some analysts stated that the results were below expectations.
BenzingaWhy Is Small-Cap Cancer Focused Vincerx Pharma Stock Plummeting On Tuesday?
On Monday, Vincerx Pharma Inc (NASDAQ:VINC) presented preliminary Phase 1 data for VIP236 and updates on pipeline progress at the American Association for Cancer Research Annual Meeting 2024. VNC-236-101 is a Phase 1 dose-escalation study with monotherapy VIP236 for metastatic tumor patients who have exhausted all standard therapy options. Fifteen patients have been dosed to date on the once-every-three-weeks (Q3W) schedule: The Q3W schedule is well tolerated with no dose-limiting toxicity (DLT)
GlobeNewswireVincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024
VIP236 demonstrated positive signs of clinical activity, including tumor reduction, and an improved safety profile in heavily pretreated patients with metastatic solid tumors VIP943 pharmacokinetic (PK) data shows very little free payload in circulation, consistent with the favorable safety profile observed preclinically and clinically In preclinical studies, Vincerx’s next-generation effector chemistry improves the efficacy of two approved antibody-drug conjugates (ADCs), highlighting VersAptx™
